Pexacerfont API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Pexacerfont API 459856-18-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Pexacerfont. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Pexacerfont
- Synonyms:
- Cas Number:
- 459856-18-9
- DrugBank number:
- DB12572
- Unique Ingredient Identifier:
- LF1VBG4ZUK
General Description:
Pexacerfont, identified by CAS number 459856-18-9, is a notable compound with significant therapeutic applications. Pexacerfont has been investigated for the treatment of Alcoholism, Anxiety Disorder, Alcohol Dependence, and Alcohol-Related Disorders.
Classification:
Pexacerfont belongs to the class of organic compounds known as pyrazolylpyridines. These are compounds containing a pyrazolylpyridine skeleton, which consists of a pyrazole linked (not fused) to a pyridine by a bond, classified under the direct parent group Pyrazolylpyridines. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Pyridines and derivatives class, specifically within the Pyrazolylpyridines subclass.
Pexacerfont is a type of Anti-anxiety
The Anti-anxiety category in the pharmaceutical API (Active Pharmaceutical Ingredient) market refers to a group of substances specifically developed to alleviate symptoms associated with anxiety disorders. Anxiety disorders are mental health conditions characterized by excessive worry, fear, and unease that can significantly impact daily life.
Pharmaceutical APIs within the Anti-anxiety category work by modulating the activity of neurotransmitters in the brain, particularly gamma-aminobutyric acid (GABA). GABA is an inhibitory neurotransmitter that helps regulate the excitability of neurons. By enhancing GABA's inhibitory effects, these APIs promote a calming effect, reducing anxiety symptoms.
Common Anti-anxiety APIs include benzodiazepines, such as alprazolam, diazepam, and lorazepam. These substances act as central nervous system depressants, inducing sedation and relaxation. Other APIs in this category include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and certain antihistamines.
Pharmaceutical companies develop and manufacture Anti-anxiety APIs to meet the growing demand for effective anxiety treatment options. These APIs are typically used as the active ingredient in the production of various anti-anxiety medications, such as tablets, capsules, or liquid formulations.
The market for Anti-anxiety APIs is influenced by factors such as increasing awareness about mental health, rising prevalence of anxiety disorders, and the growing demand for personalized treatment options. Regulatory compliance, quality control, and safety are crucial considerations in the development and production of these APIs to ensure efficacy and minimize potential side effects.
Overall, Anti-anxiety APIs play a vital role in the pharmaceutical industry by providing effective solutions for individuals struggling with anxiety disorders, enhancing their quality of life, and promoting overall well-being.
